-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$35.5047.24% Upside
Enliven Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Enliven Therapeutics, Inc.?
Enliven Therapeutics, Inc. has been rated by research analysts at Mizuho Securities, Robert W. Baird in the past 90 days.